Stock Events

Stock Events

IDL Diagnostics AB 

SEK0.3140
0
-SEK0.02-5.71%Friday 11:33

Statistics

Day High
0.32
Day Low
0.312
52W High
0.53
52W Low
0.25
Volume
22,708
Avg. Volume
173,987
Mkt Cap
72.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-22.88%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
53.11MRevenue
-12.15MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.86B
Guardant Health, Inc. specializes in liquid biopsy and genomic analysis, directly competing with AroCell's approach to cancer diagnostics.
Fulgent Genetics
FLGT
Mkt Cap591.03M
Fulgent Genetics, Inc. offers genetic testing to detect cancer, which competes with AroCell's biomarker-based cancer detection tests.
Myriad Genetics
MYGN
Mkt Cap434.25M
Myriad Genetics, Inc. specializes in molecular diagnostic tests that assess an individual's risk of developing cancer, competing with AroCell's predictive diagnostics.
Qiagen NV
QGEN
Mkt Cap9.24B
Qiagen N.V. offers technologies and products for molecular diagnostics, including cancer, competing in the same field as AroCell.
Illumina
ILMN
Mkt Cap41.23B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which are essential in cancer research and diagnostics, competing with AroCell's technologies.
Pacific Biosciences of California
PACB
Mkt Cap789.51M
Pacific Biosciences of California, Inc. offers sequencing systems that can be used in cancer research, potentially competing with AroCell's diagnostic tests.

About

Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Show More
CEO
Gustav Sten
Employees
25
Country
Sweden
ISIN
SE0003883990
WKN
000A12CNW

Listings

ST
SE
IDLDX.ST
F
DE
80R.F

0 Comments

Share your thoughts

FAQs

What is IDL Diagnostics AB stock price today?▼
The current price of IDLDX.ST is SEK0.31 SEK — it has decreased by -5.71% in the past 24 hours. Watch IDL Diagnostics AB stock price performance more closely on the chart.
What is IDL Diagnostics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange IDL Diagnostics AB stocks are traded under the ticker IDLDX.ST.
Is IDL Diagnostics AB stock price growing?▼
IDLDX.ST stock has fallen by -1.88% compared to the previous week, the month change is a -13.02% fall, over the last year IDL Diagnostics AB has showed a -13.02% decrease.
What is IDL Diagnostics AB market cap?▼
Today IDL Diagnostics AB has the market capitalization of 72.33M
When is the next IDL Diagnostics AB earnings date?▼
IDL Diagnostics AB is going to release the next earnings report on November 5, 2026.
What is IDL Diagnostics AB revenue for the last year?▼
IDL Diagnostics AB revenue for the last year amounts to 53.11M SEK.
What is IDL Diagnostics AB net income for the last year?▼
IDLDX.ST net income for the last year is -12.15M SEK.
How many employees does IDL Diagnostics AB have?▼
As of November 1, 2026, the company has 25 employees.
In which sector is IDL Diagnostics AB located?▼
IDL Diagnostics AB operates in the Health & Wellness sector.
When did IDL Diagnostics AB complete a stock split?▼
IDL Diagnostics AB has not had any recent stock splits.
Where is IDL Diagnostics AB headquartered?▼
IDL Diagnostics AB is headquartered in Stockholm, Sweden.